LOS ANGELES, CALIFORNIA – July 26th, 2023 – MetAlert, Inc. (OTC: MLRT), a pioneer in location sensitive health monitoring devices and wearable technology products announced it has received a notice of allowance for a new patent by the European Patent Office (EPO). This will be the company’s first European utility patent in the GPS SmartSole family and will cover various ways to design, protect and manufacture a GPS, Cellular, Bluetooth and Wi-Fi monitoring electronic device embedded inside an insole including the inductive charging unit. This is the fifth patent granted to Metalert around tracking and monitoring devices within footwear with particular protection on the insole format.
“We have been working on this European patent for several years and we were very pleased to hear the news about the patent allowance. The timing could not have been better as we continue to roll out new generation GPS SmartSole products across Europe and North America. This new patent will provide us additional intellectual property protection in the major Western markets as well as key markets in Japan, S Korea, Australia, and New Zealand.” said Andrew Duncan Metalert Director.
“The patent has a large number of claims, with the opportunity to file additional divisional patents in the future and offers us protection against competition as well as possibly opening up new, oftentimes lucrative, licensing and partnership opportunities. While our ongoing investment in IP demonstrates MetAlert’s commitment to enhance our competitive barriers in the market, it also helps strengthen our overall value in the wearable tech industry,” stated Patrick Bertagna MetAlert CEO.
To find out more how you can buy or become an authorized reseller contact info@metalert.com business development.
MetAlert (OTC: MLRT) and its subsidiaries occupy a commanding position in the design, development, manufacturing, distribution, sales, and licensing of GPS wearable technology, asset recovery services, wandering assistive technology, and health data collection and monitoring. With over two decades of industry expertise and a robust portfolio of patents, MetAlert is the go-to solution provider for consumers and patients grappling with mobility, cognitive, and spatial awareness challenges. This demographic represents approximately 2.9% of the global population. The Company delivers comprehensive global solutions encompassing logistics, hardware, software, and connectivity.
Notable achievements include the groundbreaking GPS SmartSole®, a fusion of Dr. Scholl’s comfort with LoJack’s tracking prowess. It stands as the world’s inaugural invisible wearable tracking device, designed for individuals susceptible to wandering due to Alzheimer’s, dementia, autism, and traumatic brain injury. MetAlert’s subscription-based model thrives on technology innovation fortified by intellectual property safeguards. The company boasts international distribution channels serving customers across 40 countries, alongside its role as a U.S. Military Government contractor. In addition to public health entities, MetAlert caters to municipalities, emergency and law enforcement agencies, private educational institutions, assisted living facilities, NGOs, senior care residences, consumers, and small enterprises. Recognizing its excess capacity within its distribution center and backend processes also presents an opportunity to expand revenue streams and diversify its operations.
General information, investor relations, wholesale licensing, consumer purchase:
213.489.3019 | Info@MetAlert.com | IR@MetAlert.com | Contact Us
MetAlert.com | Mygunalert.com | Track My Workforce | GPS SmartSole.com
MetAlert United Kingdom– In the UK, MetAlert operates from its London office.
Please contact: Nelson Skip Riddle | Email: NSRiddle@MetAlert.com | Tel: +44 7785 364100
Level 2 Security (Wholly owned subsidiary) Email: contactus@level2sec.com | www.mygunalert.com | www.ifitmoves.com
Forward Looking Statements
This news release contains forward-looking statements. The terms and phrases “expects,” “would,” “will,” “believes,” and similar terms and phrases are intended to identify these forward-looking statements. Forward-looking statements are based on estimates and assumptions made by MetAlert considering its experience and perception of current conditions and expected future developments, as well as other factors that MetAlert believes are appropriate in the circumstances. Many factors could cause MetAlert’s actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statements. Certain risk factors that may cause actual results to differ are outlined in MetAlert’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (which may be obtained on the SEC Website). These factors should be considered carefully, and readers should not rely on MetAlert’s forward-looking statements. MetAlert has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required.
Disclaimer: MetAlert does not warrant or represent that the unauthorized use of materials drawn from this document’s content will not infringe the rights of third parties who are not owned or affiliated by MetAlert. Further, MetAlert cannot be held responsible or liable for the unauthorized use of this document’s content by third parties unknown to the company.